Working Paper #2010-053
Determinants of PRO-industry interactions in pharmaceutical R&D: the case of Mexico
Interactive learning, particularly between firms and public research
organizations (PRO), nurtures the dynamics of systems of innovation.
Limited interaction contributes to explain poor performance in R&D and
ultimately, in innovation by developing countries. But why this is so?
Based on evidence from the pharmaceutical industry in Mexico, this paper
identifies some determinants of PRO-industry interaction for
pharmaceutical R&D. Particular attention is granted to factors hindering
such interactions; arguably the barriers differ throughout the diverse
stages of the R&D process. The paper decomposes the Research and
Development processes, thus it is possible to identify determinants to
interactions in each of those instances. Drug development is further
split in two stages: clinical research and drug manufacturing. The
analysis indicates that macroeconomic and business environments, firms'
strategies, ethical considerations, incentives and perceptions of
PRO-industry interaction among the agents in the system, support/hinder
interactivity in pharmaceutical R&D.
- Keywords
-
- Public research organization-industry interactions
- pharmaceuticals R&D
- Mexico
- JEL codes
-
- O31
- O54
- L65
Cite this as
APA 7th ed.Santiago-Rodriguez, F., & Dutrenit, G. (2010). Determinants of PRO-industry interactions in pharmaceutical R&D: the case of Mexico (UNU-MERIT Working Paper No. 2010-053). UNU-MERIT. https://unu-merit.nl/publications/working-papers/abstract/?id=4011